MOUNJARO®
(Tirzepatide) ELI LILLY
Composition:3
MOUJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Available in the form of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg/0.5ml in pre-filled pen injected subcutaneously.
Indications:3
MOUJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
References
1. ELREXFIO™. HIGHLIGHTS OF PRESCRIBING INFORMATIONUS 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf 2. FRUZAQLA™ (fruquintinib). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf 3. MOUNJARO® (tirzepatide). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi 4. TEZSPIRE® (tezepelumab-ekko) injection. HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s001lbl.pdf
